2-氯-N-(2,3-二氢-1H-茚-2-基)乙酰胺 | 36851-11-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 中文名称: 2-氯-N-(2,3-二氢-1H-茚-2-基)乙酰胺
• 英文名称: 2-chloro-N-(indanyl-2-yl)acetamide
• 英文别名: N-<2-Indanyl>-2-chlor-acetamid；N-(2-Indanyl)-2-chlor-acetamid；2-chloro-N-(2,3-dihydro-1H-inden-2-yl)acetamide
• CAS: 36851-11-3
• 化学式: C₁₁H₁₂ClNO
• mdl: MFCD01764041
• 分子量: 209.675
• InChiKey: YPMXQRVUYBPHMP-UHFFFAOYSA-N

物化性质

• 熔点：
  124-125 °C
• 沸点：
  404.9±44.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-硝基-2-糠酸 、 2-氯-N-(2,3-二氢-1H-茚-2-基)乙酰胺 在 4-二甲氨基吡啶 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 以59%的产率得到[2-(Indan-2-ylamino)-2-oxo-ethyl] 5-nitrofuran-2-carboxylate
  参考文献：
  名称：

  Structural and biochemical study on the inhibitory activity of derivatives of 5-nitro-furan-2-carboxylic acid for RNase H function of HIV-1 reverse transcriptase

  摘要：

  Rapid emergence of drug-resistant variants is one of the most serious problems in chemotherapy for HIV-1 infectious diseases. Inhibitors acting on a target not addressed by approved drugs are of great importance to suppress drug-resistant viruses. HIV-1 reverse transcriptase has two enzymatic functions, DNA polymerase and RNase H activities. The RNase H activity is an attractive target for a new class of antiviral drugs. On the basis of the hit chemicals found in our previous screening with 20,000 small molecular-weight compounds, we synthesized derivatives of 5-nitro-furan-2-carboxylic acid. Inhibition of RNase H enzymatic activity was measured in a biochemical assay with real-time monitoring of florescence emission from the digested RNA substrate. Several derivatives showed higher inhibitory activities that those of the hit chemicals. Modulation of the 5-nitro-furan-2-carboxylic moiety resulted in a drastic decrease in inhibitory potency. In contrast, many derivatives with modulation of other parts retained inhibitory activities to varying degrees. These findings suggest the binding mode of active derivatives, in which three oxygen atoms aligned in a straight form at the nitro-furan moiety are coordinated to two divalent metal ions located at RNase H reaction site. Hence, the nitro-furan-carboxylic moiety is one of the critical scaffolds for RNase H inhibition. Of note, the RNase H inhibitory potency of a derivative was improved by 18-fold compared with that of the original hit compound, and no significant cytotoxicity was observed for most of the derivatives showing inhibitory activity. Since there is still much room for modification of the compounds at the part opposite the nitro-furan moiety, further chemical conversion will lead to improvement of compound potency and specificity. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.12.011

文献信息

• Substituted heterocyclic compounds
  申请人：——

  公开号：US20040152890A1

  公开（公告）日：2004-08-05

  Disclosed are novel heterocyclic derivatives, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes.

  本发明涉及新型杂环衍生物，可用于治疗各种疾病状态，特别是心血管疾病，如心房和心室心律失常、间歇性跛行、普林兹梅特尔（变异型）心绞痛、稳定和不稳定性心绞痛、运动诱发性心绞痛、充血性心力衰竭和心肌梗塞。该化合物也可用于糖尿病的治疗。
• Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
  申请人：CV THERAPEUTICS, INC.

  公开号：EP1806346A1

  公开（公告）日：2007-07-11

  Disclosed are novel heterocyclic derivatives, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes.

  所公开的新型杂环衍生物可用于治疗各种疾病，尤其是心血管疾病，如房性和室性心律失常、间歇性跛行、普林兹梅塔尔（变异型）心绞痛、稳定型和不稳定型心绞痛、运动诱发心绞痛、充血性心脏病和心肌梗塞。这些化合物还可用于治疗糖尿病。
• New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties
  作者：Dmitry O. Koltun、Timothy A. Marquart、Kevin D. Shenk、Elfatih Elzein、Yuan Li、Marie Nguyen、Suresh Kerwar、Dewan Zeng、Nancy Chu、Daniel Soohoo、Jia Hao、Victoria Y. Maydanik、David A. Lustig、Khing-Jow Ng、Heather Fraser、Jeffery A. Zablocki

  DOI：10.1016/j.bmcl.2003.09.093

  日期：2004.1

  New inhibitors of palmitoylCoA oxidation were synthesized based on a structurally novel lead, CVT-3501 (1). Investigation of structure-activity relationships was conducted with respect to potency of inhibition of cardiac mitochondrial palmitoylCoA oxidation and metabolic stability. Potent and metabolically stable analogues 33, 42, and 43 were evaluated in vitro for cytochrome P450 inhibition and potentially adverse electrophysiological effects. Compound 33 was also found to have favorable pharmacokinetic properties in rat. (C) 2003 Elsevier Ltd. All rights reserved.
• US7125876B2
  申请人：——

  公开号：US7125876B2

  公开（公告）日：2006-10-24
• US7407960B2
  申请人：——

  公开号：US7407960B2

  公开（公告）日：2008-08-05